18 November 2020 | News
BV100 is a potential breakthrough hospital antibiotic to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii
Image credit: Swissbiotech
Switzerland based Bioversys has recently reached a major milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers. BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focused on developing small molecules for multidrug-resistant bacterial infections with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation, today announced that the first healthy volunteers have received BV100 in Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of BV100 in healthy human volunteers through Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies.